Mapping the landscape of Fc gamma receptor expression in multiple myeloma (MM) to optimize IgG tumour targeting antibodies

Background:
MM is an incurable and common BM cancer. Monoclonal antibodies (mAbs) are a mainstay of treatment in MM and their MoA are Fc mediated. In other hematological and non-hematological malignancies, the expression and distribution of FcyR expression has been directly linked to the efficacy of tumour targeting IgG antibodies. However there is limited understanding of a causal link between FcyR expression and tumour killing or clinical responses in MM.
Hypothesis:
We hypothesize that there is heterogeneity in the FcyR landscape in patients and this correlates to clinical responses with anti-CD38 IgG. We also hypothesize that knowledge of this landscape will enable therapeutic optimization for MM patients through informing standard of care (SoC) and the design of next-generation bi-specific antibodies